Advertisement


Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Peter Clark, MA, MD, FRCP: A Payer Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Advertisement